Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AD 214

Next Previous
Drug Profile

AD 214

Alternative Names: AD-214; i-body based therapeutics - AdAlta

Latest Information Update: 28 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AdAlta
  • Developer AdAlta; The Alfred Hospital
  • Class Antifibrotics; Eye disorder therapies; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis; Renal failure
  • No development reported Interstitial lung diseases; Wet age-related macular degeneration

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in Australia (Parenteral)
  • 28 Jun 2024 No recent reports of development identified for phase-I development in Interstitial lung diseases in Australia (IV)
  • 09 Feb 2024 AdAlta completes a phase-I clinical trials in Renal failure in Australia (IV) (NCT05914909)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top